Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Nov 21;174(1):209–218. doi: 10.1007/s10549-018-5056-8

Table 5.

Hazard ratios (HRs)a and 95% confidence intervals for the association between MetS and breast cancer mortality by breast cancer subtype γ

ER+/PR+ ER+/PR− ER−/PR−
N (Deaths)b 2,995 (169) 587 (58) 619 (89)
MetSδ
 Crude 1.87 (0.78, 4.49) 3.10 (0.63, 15.43) 0.62 (0.17, 2.30)
 Adjusted§ 1.28 (0.52, 3.16) 1.89 (0.36,10.05) 0.44 (0.11, 1.75)
Components
 High WC 1.15 (0.72, 1.84) 1.11 (0.52, 2.33) 1.21 (0.58, 2.55)
 High Cholesterol 1.21 (0.90, 1.66) 1.53 (0.89, 2.63) 1.02 (0.66, 1.56)
 High blood pressure 1.16 (0.85, 1.60) 1.25 (0.73, 2.14) 1.09 (0.70, 1.70)
 High fasting glucose 1.72 (1.00, 2.96) 0.80 (0.24, 2.64) 1.70 (0.84, 3.46)
Number of MetS Components
 0(Ref) 1.00 1.00 1.00
 1 1.18 (0.59, 2.35) 1.86 (0.54, 6.40) 0.66 (0.30, 1.45)
 2 1.91 (0.94, 3.88) 2.39 (0.65, 8.72) 0.97 (0.42, 2.25)
 3+ 1.23 (0.47, 3.22) 2.05 (0.38, 10.96) 0.50 (0.13, 2.03)

Crude model included MetS and age only.

a,§

Models were adjusted for age, race, BMI, education, region, physical activity, smoking, and marital status

b

Death, number of those who died of breast cancer; N=sample size

δ

The reference category was women without any components of MetS.

γ

ER and PR status only due to limited sample sizes on HER2 receptor status

Abbreviations: ER, estrogen receptor; MetS, metabolic syndrome; PR, progesterone receptor; Ref, reference; WC, waist circumference.

Bold indicates a statistically significant value.